Polaris Pharmaceutical-KY Announces Board Approval of Consolidated Financial Report for Q1 FY2026
Polaris Pharmaceutical-KY announced that its consolidated financial report for the first quarter of fiscal year 2026 has been approved by the board of directors. The report details revenue, net loss, total assets, and liabilities for the period.
📋 Article Processing Timeline
- 📰 Published: May 12, 2026 at 09:00
- 🔍 Collected: May 13, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 13, 2026 at 12:34 (4h 33m after Collected)
1. Date of Board Meeting or Resolution: 115/05/12
2. Date of Audit Committee Approval: 115/05/12
3. Reporting Period for Financial Report or Self-Compiled Financial Information (Start Date ~ End Date): 115/01/01 ~ 115/03/31
4. Cumulative Operating Revenue from Jan 1 to Current Period (in thousands of NTD): 37,091
5. Cumulative Gross Profit (Loss) from Jan 1 to Current Period (in thousands of NTD): (45,961)
6. Cumulative Operating Income (Loss) from Jan 1 to Current Period (in thousands of NTD): (556,353)
7. Cumulative Profit (Loss) Before Tax from Jan 1 to Current Period (in thousands of NTD): (555,884)
8. Cumulative Net Profit (Loss) for the Period from Jan 1 to Current Period (in thousands of NTD): (553,785)
9. Cumulative Net Profit (Loss) Attributable to Owners of the Parent from Jan 1 to Current Period (in thousands of NTD): (553,785)
10. Cumulative Basic Earnings (Loss) Per Share from Jan 1 to Current Period (in NTD): (0.64)
11. Total Assets at End of Period (in thousands of NTD): 7,628,591
12. Total Liabilities at End of Period (in thousands of NTD): 2,828,590
13. Net Equity Attributable to Owners of the Parent at End of Period (in thousands of NTD): 4,800,001
14. Other Matters to be Noted: None
2. Date of Audit Committee Approval: 115/05/12
3. Reporting Period for Financial Report or Self-Compiled Financial Information (Start Date ~ End Date): 115/01/01 ~ 115/03/31
4. Cumulative Operating Revenue from Jan 1 to Current Period (in thousands of NTD): 37,091
5. Cumulative Gross Profit (Loss) from Jan 1 to Current Period (in thousands of NTD): (45,961)
6. Cumulative Operating Income (Loss) from Jan 1 to Current Period (in thousands of NTD): (556,353)
7. Cumulative Profit (Loss) Before Tax from Jan 1 to Current Period (in thousands of NTD): (555,884)
8. Cumulative Net Profit (Loss) for the Period from Jan 1 to Current Period (in thousands of NTD): (553,785)
9. Cumulative Net Profit (Loss) Attributable to Owners of the Parent from Jan 1 to Current Period (in thousands of NTD): (553,785)
10. Cumulative Basic Earnings (Loss) Per Share from Jan 1 to Current Period (in NTD): (0.64)
11. Total Assets at End of Period (in thousands of NTD): 7,628,591
12. Total Liabilities at End of Period (in thousands of NTD): 2,828,590
13. Net Equity Attributable to Owners of the Parent at End of Period (in thousands of NTD): 4,800,001
14. Other Matters to be Noted: None
FAQ
How did Polaris Pharmaceutical-KY's performance for the first quarter of 2026 compare to the same period last year?
The provided information does not include a comparison to the same period last year, but it reports a net loss of NT$553,785,000.
What are the main financial indicators disclosed in this report?
Key indicators such as revenue, operating income, profit before tax, net profit, basic earnings per share, total assets, total liabilities, and equity are disclosed.
Based on this report, what can be inferred about Polaris Pharmaceutical-KY's future growth prospects?
The short-term loss suggests the impact of R&D investments, and there is potential for long-term growth, but progress in specific improvement measures will be key.